Roberto Da
Impact in
-
- Antibiotic Use and Resistance
- Pharmacology top 10%
- Drug-Induced Adverse Reactions
- Inflammatory mediators and NSAID effects
- Pharmacological Effects of Natural Compounds
Papers in
-
- SARS-CoV-2 and COVID-19 Research 3
- Tuberculosis Research and Epidemiology 3
- Co-authors
- Francesca Menniti‐Ippolito (18 shared papers)Giuseppe Traversa (17 shared papers)Roberto Raschetti (11 shared papers)Stefania Spila Alegiani (18 shared papers)Francesco Trotta (18 shared papers)G. Traversa (9 shared papers)Luca Lorenzoni (3 shared papers)Gabriela Mazzanti (2 shared papers)
- Journals
- PLoS ONE (5 papers)BMJ Open (4 papers)British Journal of Clinical Pharmacology (3 papers)European Journal of Clinical Pharmacology (3 papers)Frontiers in Pharmacology (3 papers)
- Partner nations
- ItalyArmeniaUnited States
In The Last Decade
Roberto Da
64 papers receiving 773 citations
Peers
Comparison fields: 5 of 105
- Applied Microbiology and Biotechnology 40
- Pharmacology 132
- Toxicology 22
- Pharmacology 54
- Health Information Management 26
Countries citing papers authored by Roberto Da
This map shows the geographic impact of Roberto Da's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Da with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Da more than expected).
Fields of papers citing papers by Roberto Da
This network shows the impact of papers produced by Roberto Da. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Da. The network helps show where Roberto Da may publish in the future.
Co-authors
The 25 scholars most cited alongside Roberto Da, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 67 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 64 | |
| 2 | 2009 | 41 | |
| 3 | 2014 | 36 | |
| 4 | 1999 | 36 | |
| 5 | 2011 | 33 | |
| 6 | 1995 | 32 | |
| 7 | 1998 | 31 | |
| 8 | 2020 | 28 | |
| 9 | 2013 | 28 | |
| 10 | 2016 | 27 | |
| 11 | 1998 | 26 | |
| 12 | 2004 | 22 | |
| 13 | 2019 | 21 | |
| 14 | 2014 | 21 | |
| 15 | 2021 | 20 | |
| 16 | 2014 | 20 | |
| 17 | 2001 | 20 | |
| 18 | 2017 | 19 | |
| 19 | 2019 | 17 | |
| 20 | 2009 | 17 |
About Roberto Da
Roberto Da is a scholar working on Infectious Diseases, Pharmacology, Epidemiology, Applied Microbiology and Biotechnology and Economics and Econometrics, having authored 67 papers that have together received 802 indexed citations. Recurring topics across this work include Antibiotic Use and Resistance (8 papers), Pharmaceutical Economics and Policy (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Schizophrenia research and treatment (3 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Tuberculosis Research and Epidemiology (3 papers), Urinary Tract Infections Management (2 papers) and Antibiotic Resistance in Bacteria (2 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (40 citations), Pharmacology (132 citations), Toxicology (22 citations), Pharmacology (54 citations) and Health Information Management (26 citations). Roberto Da has collaborated with scholars based in Italy, Armenia and United States. Frequent co-authors include Francesca Menniti‐Ippolito, Giuseppe Traversa, Roberto Raschetti, Stefania Spila Alegiani, Francesco Trotta, G. Traversa, Luca Lorenzoni, Gabriela Mazzanti, Paola Angela Moro and Emanuel Raschi. Their work appears in journals such as PLoS ONE, BMJ Open, British Journal of Clinical Pharmacology, European Journal of Clinical Pharmacology and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.